Loading...
Loading...
ANAB| Name | Value |
|---|---|
| Revenues | 3.5M |
| Cost of Revenue | 0.6M |
| Gross Profit | 2.9M |
| Operating Expense | 43.6M |
| Operating I/L | -40.1M |
| Other Income/Expense | 0.3M |
| Interest Income | 4.7M |
| Pretax | -39.8M |
| Income Tax Expense | 4.4M |
| Net Income/Loss | -39.8M |
AnaptysBio, Inc. is a clinical stage biotechnology company specializing in the development of therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an antibody targeting the interleukin-36 receptor (IL-36R) for dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody for human inflammatory diseases associated with immune cell dysregulation. AnaptysBio also focuses on advancing various antibody programs through collaborations and license agreements with pharmaceutical companies, positioning itself to generate revenue through product development and commercialization.
